PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma

被引：0
|
作者：
Yael Babichev
Leah Kabaroff
Alessandro Datti
David Uehling
Methvin Isaac
Rima Al-awar
Michael Prakesch
Ren X. Sun
Paul C. Boutros
Rosemarie Venier
Brendan C. Dickson
Rebecca A. Gladdy
机构：
[1] Mount Sinai Hospital,Lunenfeld
[2] Lunenfeld-Tanenbaum Research Institute,Tanenbaum Research Institute
[3] University of Perugia,Sinai
[4] Ontario Institute for Cancer Research,McLaughlin Assay and Robotic Technologies Facility
[5] University of Toronto,Department of Agricultural, Food, and Environmental Sciences
[6] Ontario Institute for Cancer Research,Drug Discovery Group
[7] University of Toronto,Department of Pharmacology and Toxicology
[8] Mount Sinai Hospital,Informatics and Biocomputing Program
[9] University of Toronto,Department of Medical Biophysics
[10] University of Toronto,Department of Pathology and Laboratory Medicine
[11] Ontario Institute for Cancer Research,Department of Surgery
[12] Lunenfeld-Tanenbaum Research Institute,Institute of Medical Science
来源：
Journal of Translational Medicine | / 14卷
关键词：
Leiomyosarcoma; PI3K; mTOR; Drug discovery; Sarcoma; Doxorubicin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
    Justin Cidado
    Ben Ho Park
    Journal of Mammary Gland Biology and Neoplasia, 2012, 17 : 205 - 216
  • [22] Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
    Cidado, Justin
    Park, Ben Ho
    JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2012, 17 (3-4) : 205 - 216
  • [23] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
  • [24] Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
    Polivka, Jiri, Jr.
    Janku, Filip
    PHARMACOLOGY & THERAPEUTICS, 2014, 142 (02) : 164 - 175
  • [25] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [26] Combination of PI3K/mTOR Inhibition Demonstrates Efficacy in Human Chordoma
    Schwab, Joseph
    Antonescu, Cristina
    Boland, Patrick
    Healey, John
    Rosenberg, Andrew
    Nielsen, Petur
    Iafrate, John
    Delaney, Thomas
    Yoon, Sam
    Choy, Edwin
    Harmon, David
    Raskin, Kevin
    Yang, Cao
    Mankin, Henry
    Springfield, Dempsey
    Hornicek, Francis
    Duan, Zhenfeng
    ANTICANCER RESEARCH, 2009, 29 (06) : 1867 - 1871
  • [27] Combination of PI3K/Akt/mTOR inhibitors and PDT in endothelial and tumor cells
    Fateye, Babasola
    Chen, Bin
    OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XX, 2011, 7886
  • [28] INHIBITION OF PI3K/MTOR PATHWAYS IN GLIOBLASTOMA AND IMPLICATIONS FOR COMBINATION THERAPY WITH ERLOTINIB, TEMOZOLOMIDE, AND RADIATION
    Prasad, Gautam
    Sottero, Theo
    Yang, Xiaodong
    Mueller, Sabine
    James, C. David
    Polley, Mei-Yin C.
    Berger, Mitchel S.
    Aftab, Dana
    Prados, Michael
    Haas-Kogan, Daphne
    NEURO-ONCOLOGY, 2009, 11 (05) : 593 - 593
  • [29] Inhibition of PI3K/mTOR Pathways In Glioblastoma and Implications for Combination Therapy with Erlotinib, Temozolomide, and Radiation
    Prasad, G.
    Sottero, T.
    Yang, X.
    Mueller, S.
    James, D.
    Berger, M.
    Aftab, D. T.
    Prados, M. D.
    Haas-Kogan, D. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S67 - S68
  • [30] Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
    LoPiccolo, Jaclyn
    Blumenthal, Gideon M.
    Bernstein, Wendy B.
    Dennis, Phillip A.
    DRUG RESISTANCE UPDATES, 2008, 11 (1-2) : 32 - 50
12345